MedTech Case Study: Seed Funding Readiness for a UK FemTech Start-Up

Interval Group worked with a UK-based FemTech start-up developing a Class II medical device to support its preparation for Seed funding. Like many early-stage MedTech companies, the business had strong technical and clinical potential but faced challenges translating this into a clear, credible investment proposition. This case study outlines how Interval combined MedTech market insight, NHS-aligned clinical expertise, and VC-facing advisory support to strengthen investor readiness and position the company for its next stage of growth.

Client Overview

UK-based FemTech start-up developing a Class II medical device for the healthcare market.

Challenge: MedTech Seed Funding Readiness

The client was preparing for its Seed funding round but faced persistent challenges securing investment throughout 2024. While the product showed strong technical promise, the start-up struggled to:

• Gain traction with MedTech and FemTech investors

• Clearly articulate its clinical and commercial value proposition

• Establish sufficient clinical credibility aligned with NHS and regulatory expectations

• Position itself effectively against competing early-stage medical device companies

  
  

The leadership team engaged Interval Group, a specialist MedTech and Life Sciences consultancy, to accelerate funding readiness and strengthen its investor narrative.

Interval Group’s Approach

Interval Group began with a detailed talent-mapping and MedTech market analysis, focusing on:

• Venture Capital firms actively investing in MedTech and FemTech start-ups

• Leadership structures and go-to-market strategies of competitor medical device companies approaching product launch

• Investor expectations for early-stage Class II medical devices

This analysis identified clear gaps in the company’s investor positioning, clinical narrative, and overall funding strategy.

To address these gaps, Interval deployed its fractional consulting model, providing the start-up with direct access to senior MedTech expertise, including:

• VP-level Medical Affairs specialists with direct NHS clinical backgrounds

• Medical Affairs leaders with prior CMO-level experience, supporting early-stage MedTech companies

• Venture Capital Principal Advisors specialising in MedTech investment and Seed-stage funding

  
  

Strategic Support Delivered

Through this fractional model, Interval Group supported the start-up with:

• Strategic guidance on Seed funding pathways and MedTech investor targeting

• Development of a clinically credible positioning strategy aligned with NHS and regulatory requirements

• Refinement of the company’s Seed Round investment narrative

• Professional restructuring and redesign of pitch materials to improve clarity, messaging, and investor impact

  
  

Results: Improved MedTech Investor Readiness

By early 2025, the start-up had significantly improved its Seed funding readiness.

Interval Group delivered:

• A clear, aligned MedTech funding strategy grounded in NHS and market realities

• Direct access to senior clinicians and VC advisors experienced in evaluating early-stage medical devices

• A transformed investor deck and pitch approach, improving differentiation in a competitive MedTech landscape

• High-impact strategic and clinical expertise delivered through a cost-effective fractional consulting model

  
  

Conclusion

Interval Group provided the strategic, clinical, and investor-facing support required to elevate the FemTech start-up’s Seed Round positioning. By combining MedTech market insight, NHS clinical expertise, and VC-aligned advisory support, Interval equipped the business with the narrative, materials, and executive-level guidance needed to pursue funding with confidence.